Literature DB >> 12406101

Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected.

Vesna Najfeld1, Lya Montella, Angela Scalise, Steven Fruchtman.   

Abstract

Between 1986 and 2001, 220 patients with polycythaemia vera (PV) were studied using conventional cytogenetics. Of 204 evaluable patients, 52 (25.4%) had clonal abnormalities. The recurrent chromosomal rearrangements were those of chromosome 9 (21.1%), del(20q) (19.2%), trisomy 8 (19.2%), rearrangements of 13q (13.4%), abnormalities of 1q (11.5%), and of chromosomes 5 and 7 (9.6%). Subsequent analysis of 32 patients, performed at follow-up of up to 14.8 years, revealed new clonal abnormalities in five patients and the disappearance of an abnormal clone in four. Eleven patients remained normal up to 11.5 years and seven patients maintained an abnormality for over 10 years. Fifty-three patients were studied retrospectively using interphase fluorescence in situ hybridization (I-FISH), utilizing probes for centromere enumeration of chromosomes 8 and 9, and for 13q14 and 20q12 loci. Conventional cytogenetics demonstrated clonal chromosome abnormalities in 23% of these 53 patients. The addition of I-FISH increased the detection of abnormalities to 29% and permitted clarification of chromosome 9 rearrangements in an additional 5.6% of patients. FISH uncovered rearrangements of chromosome 9 in 53% of patients with an abnormal FISH pattern, which represented the most frequent genomic alteration in this series.

Entities:  

Mesh:

Year:  2002        PMID: 12406101     DOI: 10.1046/j.1365-2141.2002.03763.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Authors:  Alison R Moliterno; Donna M Williams; Ophelia Rogers; Jerry L Spivak
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

2.  Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors:  Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal:  Blood Adv       Date:  2018-12-26

3.  Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.

Authors:  Raajit K Rampal; John O Mascarenhas; Heidi E Kosiorek; Leah Price; Dmitriy Berenzon; Elizabeth Hexner; Camille N Abboud; Marina Kremyanskaya; Rona Singer Weinberg; Mohamed E Salama; Kamal Menghrajani; Vesna Najfeld; Lonette Sandy; Mark L Heaney; Ross L Levine; Ruben A Mesa; Amylou C Dueck; Judith D Goldberg; Ronald Hoffman
Journal:  Blood Adv       Date:  2018-12-26

4.  In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.

Authors:  Amos Gaikwad; Roberto Nussenzveig; Enli Liu; Stephen Gottshalk; KoTung Chang; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-04       Impact factor: 3.084

5.  Quantification of clonal hematopoiesis in polycythemia vera.

Authors:  Udo Siebolts; Murat Ates; Rüdiger Spitz; Jürgen Thiele; Claudia Wickenhauser
Journal:  Virchows Arch       Date:  2005-08-19       Impact factor: 4.064

Review 6.  Gain-of-function c-CBL mutations associated with uniparental disomy of 11q in myeloid neoplasms.

Authors:  Seishi Ogawa; Masashi Sanada; Lee-Young Shih; Takahiro Suzuki; Makoto Otsu; Hiromitsu Nakauchi; H Philip Koeffler
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

7.  Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.

Authors:  Xiaoli Wang; Wei Zhang; Joseph Tripodi; Min Lu; Mingjiang Xu; Vesna Najfeld; Yan Li; Ronald Hoffman
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

8.  Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin.

Authors:  Bridget K Marcellino; Noushin Farnoud; Bruno Cassinat; Min Lu; Emanuelle Verger; Erin McGovern; Minal Patel; Juan Medina-Martinez; Max Fine Levine; Juanes E Arango Ossa; Yangyu Zhou; Heidi Kosiorek; Meenakshi Mehrotra; Jane Houldsworth; Amylou Dueck; Michael Rossi; John Mascarenhas; Jean-Jacques Kiladjian; Raajit K Rampal; Ronald Hoffman
Journal:  Blood Adv       Date:  2020-11-24

9.  Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.

Authors:  Donna M Williams; Ann H Kim; Ophelia Rogers; Jerry L Spivak; Alison R Moliterno
Journal:  Exp Hematol       Date:  2007-10-17       Impact factor: 3.084

10.  Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays.

Authors:  Go Yamamoto; Yasuhito Nannya; Motohiro Kato; Masashi Sanada; Ross L Levine; Norihiko Kawamata; Akira Hangaishi; Mineo Kurokawa; Shigeru Chiba; D Gary Gilliland; H Phillip Koeffler; Seishi Ogawa
Journal:  Am J Hum Genet       Date:  2007-06-05       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.